TR199802034T2 - Çapraz baglantili amylose ve hydroxypropylmethylcellulose bazinda bir tasiyici içeren kontrollü çözülümlü farmasötik tablet. - Google Patents

Çapraz baglantili amylose ve hydroxypropylmethylcellulose bazinda bir tasiyici içeren kontrollü çözülümlü farmasötik tablet.

Info

Publication number
TR199802034T2
TR199802034T2 TR1998/02034T TR9802034T TR199802034T2 TR 199802034 T2 TR199802034 T2 TR 199802034T2 TR 1998/02034 T TR1998/02034 T TR 1998/02034T TR 9802034 T TR9802034 T TR 9802034T TR 199802034 T2 TR199802034 T2 TR 199802034T2
Authority
TR
Turkey
Prior art keywords
tablet
amylose
farmas
apraz
kontroll
Prior art date
Application number
TR1998/02034T
Other languages
English (en)
Inventor
Chouinard Fran�Ois
Jacques Wilfrid
Original Assignee
Labopharm Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Inc. filed Critical Labopharm Inc.
Publication of TR199802034T2 publication Critical patent/TR199802034T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En az bir aktif ana maddesinden belli bir miktarda agizdan verilmesi ve bu maddenin kontrollü bir sekilde çözülmesini saglamak amaciyla hazirlanmis bir farmasötik tablet. Bilesim agirliga göre en fazla %60 oraninda aktif madde ile karistirilip sikistirilmis 100 gram amylose'a 0.1-10 gram retikülasyon maddesine tekabül eden miktarlarda bir retikülasyon maddesi yardimiyla retiküler edilmis en az %40 oraninda amylose tasiyici içerir. Tasiyici, %30-90 retiküle amylose ve en az 4000 cps viskoziteyle %10-30 hydroxypropylmethylcellulose (HPMC) içerir ve bu yüzdeler tabletin toplam agirligina göredir. Elde edilen tabletlerin enzim ortamina mükemmel bir direnci olup, ortamdaki enzim konsantrasyonuna daha az baglidir.
TR1998/02034T 1996-04-10 1997-04-04 Çapraz baglantili amylose ve hydroxypropylmethylcellulose bazinda bir tasiyici içeren kontrollü çözülümlü farmasötik tablet. TR199802034T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002173818A CA2173818A1 (fr) 1996-04-10 1996-04-10 Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Publications (1)

Publication Number Publication Date
TR199802034T2 true TR199802034T2 (tr) 1999-02-22

Family

ID=4157953

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/02034T TR199802034T2 (tr) 1996-04-10 1997-04-04 Çapraz baglantili amylose ve hydroxypropylmethylcellulose bazinda bir tasiyici içeren kontrollü çözülümlü farmasötik tablet.

Country Status (22)

Country Link
US (1) US5885615A (tr)
EP (1) EP0954290B1 (tr)
JP (1) JP4166278B2 (tr)
KR (1) KR100439614B1 (tr)
CN (1) CN1218396A (tr)
AT (1) ATE240719T1 (tr)
AU (1) AU711089B2 (tr)
BR (1) BR9708772A (tr)
CA (1) CA2173818A1 (tr)
CZ (1) CZ294342B6 (tr)
DE (1) DE69722247T2 (tr)
DK (1) DK0954290T3 (tr)
ES (1) ES2200166T3 (tr)
IL (1) IL126477A (tr)
MY (1) MY115535A (tr)
NO (1) NO321862B1 (tr)
NZ (1) NZ332576A (tr)
PL (1) PL187764B1 (tr)
PT (1) PT954290E (tr)
TR (1) TR199802034T2 (tr)
WO (1) WO1997037639A1 (tr)
ZA (1) ZA973054B (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6416786B1 (en) 1998-12-11 2002-07-09 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
EP1174127A1 (en) * 2000-07-21 2002-01-23 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Composition for targeted release of an actvie substance and process for producing such a composition
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
MXPA05004410A (es) * 2002-10-25 2005-11-23 Labopharm Inc Composiciones de liberacion controlada.
MY142195A (en) * 2002-10-25 2010-10-15 Labopharm Inc Controlled-release compositions
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004047651A2 (en) * 2002-11-25 2004-06-10 Boston Scientific Limited Injection device for treating mammalian body
JP2006515008A (ja) * 2003-01-28 2006-05-18 コレギウム ファーマシューティカル， インコーポレイテッド 経口投与のためのミルナシプランの多粒子状組成物
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
JP5269595B2 (ja) * 2005-09-09 2013-08-21 アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー １日１回投与用トラゾドン組成物
WO2007035865A1 (en) * 2005-09-21 2007-03-29 Surmodics, Inc. Coatings and articles including natural biodegradable polysaccharides
CN101309709A (zh) * 2005-09-21 2008-11-19 苏尔莫迪克斯公司 包含天然生物可降解的多糖的涂层和物品
EP1946780B1 (en) * 2005-11-11 2012-01-11 Asahi Kasei Chemicals Corporation Controlled release solid preparation
WO2008073295A2 (en) * 2006-12-07 2008-06-19 Surmodics, Inc. Latent stabilization of bioactive agents releasable from implantable medical articles
US8936811B2 (en) 2008-05-07 2015-01-20 Surmodics, Inc. Device coated with glycogen particles comprising nucleic acid complexes
SI2323633T1 (sl) * 2008-09-04 2012-07-31 Bristol Myers Squibb Co Stabilni farmacevtski sestavek za optimizirano razdeljevanje hiv pripetih inhibitorjev
EP2362768B1 (en) * 2008-10-27 2016-04-20 Alza Corporation Extended release oral acetaminophen/tramadol dosage form
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
CA2041774C (en) * 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
NL9201196A (nl) * 1992-07-03 1994-02-01 Tno Preparaat voor de gereguleerde afgifte van een werkzame stof en werkwijze ter bereiding van een dergelijk preparaat.
JP3647859B2 (ja) * 1992-07-24 2005-05-18 ラボファーム・インコーポレーテッド 酵素的に制御された薬剤放出のための架橋されたポリヒドロキシ材料
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Also Published As

Publication number Publication date
PL187764B1 (pl) 2004-10-29
US5885615A (en) 1999-03-23
NO984703L (no) 1998-12-08
BR9708772A (pt) 2000-01-04
PT954290E (pt) 2003-10-31
IL126477A (en) 2001-10-31
DE69722247D1 (de) 2003-06-26
EP0954290B1 (fr) 2003-05-21
DE69722247T2 (de) 2004-04-01
CZ325498A3 (cs) 1999-03-17
AU2283297A (en) 1997-10-29
PL329285A1 (en) 1999-03-15
ES2200166T3 (es) 2004-03-01
CA2173818A1 (fr) 1997-10-11
MY115535A (en) 2003-07-31
ATE240719T1 (de) 2003-06-15
NO984703D0 (no) 1998-10-08
IL126477A0 (en) 1999-08-17
AU711089B2 (en) 1999-10-07
JP4166278B2 (ja) 2008-10-15
CN1218396A (zh) 1999-06-02
EP0954290A1 (fr) 1999-11-10
KR20000005337A (ko) 2000-01-25
NZ332576A (en) 2000-03-27
CZ294342B6 (cs) 2004-12-15
ZA973054B (en) 1998-06-01
NO321862B1 (no) 2006-07-17
WO1997037639A1 (fr) 1997-10-16
DK0954290T3 (da) 2003-09-22
JP2000507561A (ja) 2000-06-20
KR100439614B1 (ko) 2004-10-14

Similar Documents

Publication Publication Date Title
TR199802034T2 (tr) Çapraz baglantili amylose ve hydroxypropylmethylcellulose bazinda bir tasiyici içeren kontrollü çözülümlü farmasötik tablet.
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
DE69636724D1 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
ATE161174T1 (de) Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung
IL180924A (en) Method for regulating cell proliferation and cell death
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
GT199800152A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
CA2140032A1 (en) Cross-linked amylose material for enzymatically controlled drug release
ES8608313A1 (es) Procedimiento para preparar microcapsulas con liberacion controlada de la substancias activa, que contienen peptidos,reguladores y un material de soporte biologicamente degradable.
AU7415181A (en) Polymeric diffusion matrix for administration of drugs
NO942228L (no) Ipsapiron-legemiddeltilberedning
MXPA98008158A (es) Composicion anti-vih que contiene derivados de imidazol.
AU6816787A (en) (Gem-heterocyclodimethanamine-N,N') platinum complexes
HUP9902681A2 (hu) Térhálósított amilózt és hidroxi-propil-metil-cellulózt tartalmazó hordozóval készült szabályozott felszabadulású tabletta gyógyszerkészítmény
IL128768A0 (en) Transdermal therapeutic system containing oestriol